MLYS Mineralys Therapeutics, Inc.
USHealthcareAs of 2026-07-09 16:00
Why MLYS matters now
Mineralys Therapeutics, Inc. (MLYS) is a US stock in Healthcare. The latest InvestLog snapshot shows $28.96 with -4.74% on the session and $1.92B in market capitalization; recent performance reads 1-month -5.38% and YTD -32.13%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-39.3M, and EPS of $-0.47. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -8.4%.
The latest indexable market news headline is "What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision" from Fool - Investing News.
Additional event context on this page matters because analyst consensus is Buy with a median target of $43.00; recent insider activity includes Karydas Daphne filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.20
P/S
0.00
EV/EBITDA
-10.02
DCF Value
$2.53
FCF Yield
-8.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-27.9%
ROA
-23.2%
ROIC
-26.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-39.3M | $-0.47 |
| Q4 2025 | $0.00 | $-32.2M | $-0.40 |
| FY 2025 | $0.00 | $-154.7M | $-2.29 |
| Q3 2025 | $0.00 | $-36.9M | $-0.52 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$43.00
Target (Median)
$43.00
Target Range
$30.00 - $56.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.56
Mineralys Therapeutics, Inc. (MLYS) is a pioneering biopharmaceutical company currently advancing through clinical trials. Its primary focus lies in creating innovative treatments for high blood pressure and its related cardiovascular complications. The company's leading investigational drug is lorundrostat. This exclusive, orally administered compound functions as a highly targeted aldosterone synthase inhibitor, specifically being developed to address difficult-to-treat cases of uncontrolled or resistant hypertension. Established in 2019, Mineralys Therapeutics operates from its headquarters in Radnor, Pennsylvania.